Biocon share news, announcements and annual reports
NSE: BIOCONBSE: 532523Pharmaceuticals & BiotechnologyMid Cap
Biocon Limited · Face value ₹5 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 2004
Last close ₹351.80down ₹0.10 (0.03%)BSE ₹352.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹351.90.
30 Oct: open ₹352.70, high ₹355.50, low ₹348.70
52-week range of traded prices to 30 Oct 2026
₹318.40Low, 23 Oct 2026₹447.15High, 16 Jul 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹57,333 Cr173rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 115.75
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹399 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 64.09
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.68
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.14%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 1.8%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹399 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 3.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 2.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 20,63,63747.1% delivered
Biocon share news and announcements
1,771 announcements, routine notices left out, newest first. Page 33 of 36.
Jul 2011
21 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2011 as follows: Net Sales of Rs. 33890 lacs for quarter ending on 30-JUN-2011 against Rs. 32240 lacs for the quarter ending on 30-JUN-2010. Net Profit / (Loss) of Rs. 6040 lacs for the quarter ending on 30-JUN-2011 against Rs. 7230 lacs for the quarter ending on 30-JUN-2010.21 Jul · Results
Consolidated Results for the quarter ended on 30-JUN-2011 as follows: Net Sales of Rs. 44168 lacs for quarter ending on 30-JUN-2011 against Rs. 66228 lacs for the quarter ending on 30-JUN-2010. Net Profit / (Loss) of Rs. 7005 lacs for the quarter ending on 30-JUN-2011 against Rs. 7674 lacs for the quarter ending on 30-JUN-2010.1 Jul · Board meeting
Inter alia, to approve and take on record the unaudited financial results of the Company for the quarter ended on June 30, 2011.
Jun 2011
17 Jun · Meeting
Company has announced the Book Closure from July 09, 2011 to July 21, 2011 (both days inclusive) for the purpose of Annual General Meeting and Final Dividend. Further, the Annual General Meeting will be held on July 21, 2011.
May 2011
4 May · Dividend
Payment date for the interim dividend of Rs.1.50 per equity share declared by the Board of Directors of the Company in its meeting held on April 28, 2011 will be May 12, 2011.3 May · Management
Board of Directors in its meeting held on April 28, 2011 have appointed Mr. John Russell Fotheringham Walls as an Additional Director of the Company with immediate effect. He will hold office up to the date of the Annual General Meeting, when his appointment as a director will be placed for the approval of the shareholders.
Apr 2011
28 Apr · Dividend
Board of Directors of the Company at its meeting held on April 28, 2011 have declared an interim dividend of 30% (Rs 1.50 per share). A final dividend of 60% (Rs. 3.00 per share), has also been recommended by the Board subject to the approval of the members thereby taking the total dividend for the year to 90% (Rs. 4.50 per share) on the share capital of the Company.28 Apr · Results
Consolidated Results for the year ended on 31-MAR-2011 as follows: Net Sales of Rs. 277073 lacs for year ending on 31-MAR-2011 against Rs. 236782 lacs for the year ending on 31-MAR-2010. Net Profit / (Loss) of Rs. 36752 lacs for the year ending on 31-MAR-2011 against Rs. 29325 lacs for the year ending on 31-MAR-2010.28 Apr · Results
Standalone Results for the quarter ended on 31-MAR-2011 as follows: Net Sales of Rs. 37136 lacs for quarter ending on 31-MAR-2011 against Rs. 32732 lacs for the quarter ending on 31-MAR-2010. Net Profit / (Loss) of Rs. 8803 lacs for the quarter ending on 31-MAR-2011 against Rs. 7264 lacs for the quarter ending on 31-MAR-2010.28 Apr · Results
Standalone Results for the year ended on 31-MAR-2011 as follows: Net Sales of Rs. 153156 lacs for year ending on 31-MAR-2011 against Rs. 116309 lacs for the year ending on 31-MAR-2010. Net Profit / (Loss) of Rs. 45925 lacs for the year ending on 31-MAR-2011 against Rs. 24836 lacs for the year ending on 31-MAR-2010.28 Apr · Results
Consolidated Results for the quarter ended on 31-MAR-2011 as follows: Net Sales of Rs. 70163 lacs for quarter ending on 31-MAR-2011 against Rs. 65684 lacs for the quarter ending on 31-MAR-2010. Net Profit / (Loss) of Rs. 10081 lacs for the quarter ending on 31-MAR-2011 against Rs. 8062 lacs for the quarter ending on 31-MAR-2010.25 Apr · Corporate action
Board of Directors at its meeting held on April 28, 2011 has fixed May 06, 2011 as the record date for payment of the Interim Dividend, if any, declared by the Board of Directors in their meeting to be held on April 28, 2011.18 Apr · Board meeting
Inter alia, to approve and take on record the audited financial results of the company for the year ended on March 31, 2011 and to consider payment of interim dividend and recommendation of final dividend for the Financial year 2010-2011.
Jan 2011
20 Jan · Results
Standalone Results for the quarter ended on 31-DEC-2010 as follows: Net Sales of Rs. 50168 lacs for quarter ending on 31-DEC-2010 against Rs. 30083 lacs for the quarter ending on 31-DEC-2009. Net Profit / (Loss) of Rs. 21159 lacs for the quarter ending on 31-DEC-2010 against Rs. 6580 lacs for the quarter ending on 31-DEC-2009.4 Jan · Board meeting
Inter alia, to approve and take on record the unaudited financial results of the Company for the quarter ended on December 31, 2010.
Oct 2010
22 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2010 as follows: Net Sales of Rs. 33612 lacs for quarter ending on 30-SEP-2010 against Rs. 29215 lacs for the quarter ending on 30-SEP-2009. Net Profit / (Loss) of Rs. 8733 lacs for the quarter ending on 30-SEP-2010 against Rs. 6236 lacs for the quarter ending on 30-SEP-2009.22 Oct · Results
Consolidated Results for the quarter ended on 30-SEP-2010 as follows: Net Sales of Rs. 67877 lacs for quarter ending on 30-SEP-2010 against Rs. 57993 lacs for the quarter ending on 30-SEP-2009. Net Profit / (Loss) of Rs. 8922 lacs for the quarter ending on 30-SEP-2010 against Rs. 7419 lacs for the quarter ending on 30-SEP-2009.5 Oct · Board meeting
Inter alia, to approve and take on record the unaudited financial results of the Company for the quarter ended on September 30, 2010.
Sep 2010
Aug 2010
Jul 2010
23 Jul · Results
Consolidated Results for the quarter ended on 30-JUN-2010 as follows: Net Sales of Rs. 66228 lacs for quarter ending on 30-JUN-2010 against Rs. 49593 lacs for the quarter ending on 30-JUN-2009. Net Profit / (Loss) of Rs. 7674 lacs for the quarter ending on 30-JUN-2010 against Rs. 5755 lacs for the quarter ending on 30-JUN-2009.23 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2010 as follows: Net Sales of Rs. 32240 lacs for quarter ending on 30-JUN-2010 against Rs. 24279 lacs for the quarter ending on 30-JUN-2009. Net Profit / (Loss) of Rs. 7230 lacs for the quarter ending on 30-JUN-2010 against Rs. 4755 lacs for the quarter ending on 30-JUN-2009.7 Jul · Board meeting
Inter alia, to approve and take on record the unaudited financial results of the Company for the quarter ended on June 30, 2010.
Jun 2010
May 2010
21 May · Meeting
Company has announced the Book Closure from July 10, 2010 to July 23, 2010 (both days inclusive) for the purpose of Annual General Meeting and Dividend. Further, the Annual General Meeting will be held on July 23, 2010.
Apr 2010
29 Apr · Business
Press release dated April 29, 2010, titled "Clinigene Announces Appointment of its New COO". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.29 Apr · Updates
Copy for Fact Sheet for 'FY2010 vs. FY2009; Q4 FY 2010 vs Q4 FY 2009'. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.29 Apr · Dividend
Board for Directors of the Company at their meeting held on April 29, 2010 have recommended, subject to the approval of the members dividend of 70% (Rs. 3.50) per share on the enhanced share capital of the company.29 Apr · Results
Consolidated Results for the quarter ended on 31-MAR-2010 as follows: Net Sales of Rs. 65684 lacs for quarter ending on 31-MAR-2010 against Rs. 46626 lacs for the quarter ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 8062 lacs for the quarter ending on 31-MAR-2010 against Rs. 2488 lacs for the quarter ending on 31-MAR-2009.29 Apr · Results
Consolidated Results for the year ended on 31-MAR-2010 as follows: Net Sales of Rs. 236782 lacs for year ending on 31-MAR-2010 against Rs. 160867 lacs for the year ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 29325 lacs for the year ending on 31-MAR-2010 against Rs. 9312 lacs for the year ending on 31-MAR-2009.29 Apr · Business
Press release dated April 29, 2010, titled "Biocon revenues cross half-billion dollar mark, Revenues at Rs.2,405 crores; EBITDA at Rs. 509 crores; PAT at Rs. 293 crores; Board recommends dividend of Rs. 3.50 per Equity Shares (70%)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.29 Apr · Results
Standalone Results for the year ended on 31-MAR-2010 as follows: Net Sales of Rs. 116309 lacs for year ending on 31-MAR-2010 against Rs. 91234 lacs for the year ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 24836 lacs for the year ending on 31-MAR-2010 against Rs. 11181 lacs for the year ending on 31-MAR-2009.29 Apr · Results
Standalone Results for the quarter ended on 31-MAR-2010 as follows: Net Sales of Rs. 32732 lacs for quarter ending on 31-MAR-2010 against Rs. 22160 lacs for the quarter ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 7264 lacs for the quarter ending on 31-MAR-2010 against Rs. 2414 lacs for the quarter ending on 31-MAR-2009.6 Apr · Business
Press release dated April 05, 2010, titled "Biocon Biopharmaceuticals Private Limited becomes wholly owned subsidiary". A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.